Post-Viral Recovery
83
상호작용
3
2,100
intermediate
May 17, 2026
개요
The Post-Viral Recovery stack is designed for individuals experiencing persistent fatigue, immune dysregulation, and inflammatory symptoms following viral infections — including but not limited to long COVID, post-EBV syndromes, and chronic fatigue syndrome with viral triggers. The protocol increases Thymosin Alpha-1 frequency to 3x weekly (from the standard 2x) to provide more aggressive immune reconstitution. Ta1''s ability to restore T-cell subset ratios (CD4/CD8 balance), enhance dendritic cell maturation, and promote interferon production makes it the cornerstone of post-viral immune recovery. Clinical data from COVID-19 treatment showed Ta1 reduced mortality and improved T-cell counts in critically ill patients. LL-37 is the only human cathelicidin — an antimicrobial peptide produced by neutrophils, macrophages, and epithelial cells as a first-line defense against pathogens. Beyond direct antimicrobial activity (it disrupts bacterial and viral membranes), LL-37 modulates immune cell recruitment, promotes wound healing, and importantly, helps resolve chronic inflammation by promoting macrophage phenotype switching from M1 (pro-inflammatory) to M2 (resolving/repair). In post-viral syndromes, persistent M1-dominant inflammation drives ongoing symptoms; LL-37 may help break this cycle. BPC-157 at twice-daily dosing provides systemic anti-inflammatory support and gut healing — critical because many post-viral syndromes involve gut barrier disruption and microbial translocation that perpetuate immune activation. Its modulation of the nitric oxide system and multiple growth factor pathways creates a tissue-repair environment throughout the body. The three-peptide combination addresses post-viral recovery comprehensively: Ta1 restores immune competence, LL-37 resolves chronic inflammation and provides antimicrobial coverage, and BPC-157 repairs tissue damage and restores gut barrier function. This is classified as intermediate due to the three-compound regimen and the clinical complexity of post-viral conditions.
용량 프로토콜
1,500 mcg
1회 용량당
100 mcg
1회 용량당
250 mcg
1회 용량당
목표 및 증거
경고
- LL-37 is an antimicrobial peptide with emerging research for post-viral syndromes. Limited human data outside of wound healing. Thymosin Alpha-1 remains FDA Category 2 (restricted) in the US (approved abroad as Zadaxin).
Comments
Sign in to join the discussion
주의: 이 스택은 커뮤니티에서 제출된 것이며 연구용으로만 사용됩니다. Peptide Contacts는 제출된 스택의 안전성이나 효능을 검증하지 않습니다. 펩타이드 프로토콜을 사용하기 전에 항상 자격이 있는 의료 전문가와 상의하세요.